Acorda Therapeutics Announces Filing of Patent Extension Applications for ... - MarketWatch (press release) PDF Print
MarketWatch (press release)AMPYRA is contraindicated in patients with moderate or severe renal impairment (CrClless-than or equal to 50 mL/min); the risk of seizures in patients with

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.